Skip to main content

Table 3 Perceived facilitators and barriers to acceptance and completion of 3HP expressed in terms of their Behavioral determinants within the COM-B model

From: Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives

Behavioral Determinants  Emergent themes
PLHIV Health workers
Facilitators
Capability (psychological) • Aware of being potentially at risk of TB
• Awareness of easy transmission of TB
• Knowledge that TB causes the highest mortality among PLHIV at the clinic
Opportunity (physical)   • Streamlined clinic visits
Motivation (reflective) • Willingness to take TPT
• Trust in health workers
• Perceived benefits of DOT/SAT
• PLHIV trust health workers
• PLHIV are receptive to TPT
• Convenience of once-weekly 3HP dosing schedule
• Perceived benefits of DOT/SAT
Motivation (automatic) • Fear of contracting TB • PLHIV fear TB
Barriers
Capability (physical) • Potential pill burden (difficulty to swallow many pills) • Technology challenges
• Potential pill burden (difficulty to swallow many pills)
Capability (psychological) • Inadequate understanding of TPT • Inadequate understanding of TB and TPT
Opportunity (social)   • Stigma associated with TB
Motivation (reflective) • Perceived challenges of DOT/SAT
• Concerns about the effectiveness of 3HP
• Perceived challenges of DOT/SAT
Motivation (automatic) • Fear of potential side effects • PLHIV’s fear of potential side effects
  1. Abbreviations: 3HP rifapentine-Isoniazid combination, COM-B capability opportunity motivation behavior model, TB tuberculosis, PLHIV person/people living with HIV, TPT tuberculosis preventive therapy, DOT directly observed therapy, SAT self-administered therapy